Enda McVeigh
Abstract
Open-access reader
Abstract Ulipristal acetate is the first progesterone receptor modulator licensed for the preoperative treatment of uterine fibroids. Our New products review presents the clinical data relating to its efficacy and adverse events and considers its place in medical management of uterine fibroids.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Abstract Ulipristal acetate is the first progesterone receptor modulator licensed for the preoperative treatment of uterine fibroids. Our New products review presents the clinical data relating to its efficacy and adverse events and considers its place in medical management of uterine fibroids.
Key concepts: Ulipristal acetate, Uterine fibroids, Medicine, Gynecology, Adverse effect, Internal medicine, Research methodology, Family planning